XML 72 R11.htm IDEA: XBRL DOCUMENT
v2.4.0.8

INTANGIBLE ASSETS | 12 Months Ended
--- | ---
Dec. 31, 2013
INTANGIBLE ASSETS |
INTANGIBLE ASSETS | NOTE 5 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the CFDA. The Company did not obtain CFDA production approval for any medical formula during the year ended December 31, 2013 and no costs were reclassified from advances to intangible assets in 2013. During the year ended December 31, 2012, the Company received production approval from the CFDA for one medical formula and reclassified $507,174 from advances to intangible assets. The new medical formula is being amortized from the date CFDA approval was received over its estimated useful life of thirteen years and is not expected to have a residual value at the end of its useful life. Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $766,318 and $611,724 for the years ended December 31, 2013 and 2012, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. As a result of the evaluations, the Company determined that it is not likely that the carrying value of two medical formulas will be realized from future cash flows due to the failure to meet certain enhanced technical criteria for one formula and from pricing pressures on the other one. As a result, impairment losses relating to those intangible assets were $593,095 for the year ended December 31, 2012. No impairment losses were recognized during the year ended December 31, 2013. Intangible assets consisted solely of CFDA approved medical formulas as follows:
|  | December 31, |
|  | 2013 |  |  | 2012 |
Gross carrying amount |  | $ | 5,524,785 |  |  | $ | 5,357,580 |
Accumulated amortization |  |  | (3,812,992 | ) |  |  | (2,944,726 | )
Net carrying amount |  | $ | 1,711,793 |  |  | $ | 2,412,854 |
The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:
| Year |  | Amount
| 2014 |  | $ 515,810
| 2015 |  | 452,229
| 2016 |  | 284,292
| 2017 |  | 152,841
| 2018 |  | 46,390
| Thereafter |  | 260,231
| Total |  | $ 1,711,793

X
- Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 44, 45, 46 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration